Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Preliminary results
T2 Biosystems, Inc. (TTOO) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/11/2023 8-K Quarterly results, Conference call transcript
Docs: "T2 Biosystems Announces Second Quarter 2023 Financial Results",
"Transcript of conference call held on August 7, 2023"
07/12/2023 8-K Quarterly results
05/25/2023 8-K Quarterly results, Conference call transcript
Docs: "T2 Biosystems Announces First Quarter 2023 Financial Results",
"Transcript of conference call held on May 23, 2023"
03/16/2023 8-K Quarterly results, Conference call transcript
Docs: "T2 Biosystems Announces Fourth Quarter and Full Year 2022 Financial Results",
"Transcript of conference call held on March 13, 2023"
11/10/2022 8-K Quarterly results
08/17/2022 8-K Quarterly results
05/11/2022 8-K Quarterly results
02/17/2022 8-K Quarterly results, Conference call transcript
Docs: "T2 Biosystems Announces Fourth Quarter & Full Year 2021 Financial Results",
"Transcript of conference call held on February 17, 2022"
11/05/2021 8-K Quarterly results, Conference call transcript
Docs: "T2 Biosystems Announces Third Quarter 2021 Financial Results",
"Transcript of conference call held on November 4, 2021"
08/10/2021 8-K Quarterly results, Conference call transcript
Docs: "T2 Biosystems Announces Second Quarter 2021 Financial Results",
"Transcript of conference call held on August 5, 2021"
03/09/2021 8-K Quarterly results
11/06/2020 8-K Quarterly results, Conference call transcript
Docs: "T2 Biosystems Announces Third Quarter 2020 Financial Results",
"Transcript of conference call held on November 4, 2020"
08/17/2020 8-K Quarterly results
05/08/2020 8-K Quarterly results
02/27/2020 8-K Quarterly results
01/09/2020 8-K Quarterly results
Docs: "T2 Biosystems Announces Preliminary Fourth Quarter 2019 Financial Results"
11/13/2019 8-K Quarterly results
08/01/2019 8-K Quarterly results
Docs: "T2 Biosystems Reports Second Quarter 2019 Financial Results and Provides Corporate Update",
"Transcript of conference call held by T2 Biosystems, Inc. on July 30, 2019"
05/08/2019 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : May 2, 2019 T2 BIOSYSTEMS, INC. Delaware 001-36571 20-4827488 101 Hartwell Avenue, Lexington, Massachusetts 02421 761-4646 N/A Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencement communications pursuant to Rule 13e-4 under the Excha...",
"T2 Biosystems Reports First Quarter 2019 Financial Results and Provides Corporate Update Exceeds Q1 Guidance with Delivery of $1.8 Million in Revenue and 11 New Instrument Contracts Confirms 2019 Guidance of a Doubling of Revenue and Securing 70 - 80 T2Dx Instrument Contracts LEXINGTON, Mass., May 2, 2019 — T2 Biosystems, Inc. , a leader in the development and commercialization of innovative medical diagnostic products for critical unmet needs in healthcare, announced today the operating highlights and financial results for the first quarter ended March 31, 2019. First Quarter and Recent Business and Financial Performance Highlights:",
"Transcript of conference call held by T2 Biosystems, Inc. on May 2, 2019"
03/13/2019 8-K Quarterly results
Docs: "FORM 8-K",
"T2 Biosystems Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update Secured 14 New Instrument Contracts in the Fourth Quarter and 39 total New Instrument Contracts in 2018 that are expected to drive growth in Recurring Test Revenue Confirms Guidance of a Doubling of Revenue in 2019; Provides Guidance of Securing 70 - 80 T2Dx Instruments Contracts in 2019 LEXINGTON, Mass., March 7, 2019 — T2 Biosystems, Inc. , a leader in the development and commercialization of innovative medical diagnostic products for critical unmet needs in healthcare, announced today the operating highlights and financial results for the fourth quarter and year ended December 31, 2018. Fourth Quarter and Recent Business and Financial Performance Highlights:",
"Transcript of conference call held by T2 Biosystems, Inc. on March 7, 2019"
11/06/2018 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : November 1, 2018 T2 BIOSYSTEMS, INC. Delaware 001-36571 20-4827488 101 Hartwell Avenue, Lexington, Massachusetts 02421 761-4646 N/A Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencement communications pursuant to Rule 13e-4 under the ...",
"T2 Biosystems Reports Third Quarter 2018 Financial Results and Provides Corporate Update Quarterly Product Revenue Up 71% Year-Over-Year Reiterates 2018 Financial Guidance LEXINGTON, Mass., November 1, 2018 — T2 Biosystems, Inc. , a leader in the development and commercialization of innovative medical diagnostic products for critical unmet needs in healthcare, announced today the operating highlights and financial results for the third quarter ended September 30, 2018. Third Quarter Business and Financial Performance Highlights:",
"Transcript of conference call held by T2 Biosystems, Inc. on November 1, 2018"
08/07/2018 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : August 2, 2018 T2 BIOSYSTEMS, INC. Delaware 001-36571 20-4827488 101 Hartwell Avenue, Lexington, Massachusetts 02421 761-4646 N/A Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencement communications pursuant to Rule 13e-4 under the Ex...",
"T2 Biosystems Reports Second Quarter 2018 Financial Results and Provides Corporate Update Quarterly Product Revenue Up 71% Year-Over-Year Launched the Recently FDA Cleared T2Bacteria Panel, the Flagship Product in the T2Direct Diagnostics Portfolio Reiterates 2018 Financial Guidance, Including Increase to Lower End of Revenue Guidance Range LEXINGTON, Mass., August 2, 2018 — T2 Biosystems, Inc. an emerging leader in the development and commercialization of innovative medical diagnostic products for critical unmet needs in healthcare, announced today operating highlights and financial results for the second quarter ended June 30, 2018. Second Quarter Business and Financial Performance Highlights:",
"Transcript of conference call held by T2 Biosystems, Inc. on August 2, 2018"
05/11/2018 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : May 8, 2018 T2 BIOSYSTEMS, INC. Delaware 001-36571 20-4827488 101 Hartwell Avenue, Lexington, Massachusetts 02421 761-4646 N/A Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencement communications pursuant to Rule 13e-4 under the Excha...",
"T2 Biosystems Reports First Quarter 2018 Financial Results and Provides Corporate Update Quarterly Product Revenue Up 66% Year-Over-Year On Track for Potential FDA Clearance of T2Bacteria Panel in the Second Quarter 2018 LEXINGTON, Mass., May 8, 2018 — T2 Biosystems, Inc. an emerging leader in the development and commercialization of innovative medical diagnostic products for critical unmet needs in healthcare, announced today operating highlights and financial results for the first quarter ended March 31, 2018. First Quarter Business and Financial Performance Highlights:",
"Transcript of conference call held by T2 Biosystems, Inc. on May 8, 2018"
03/09/2018 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : March 6, 2018 T2 BIOSYSTEMS, INC. Delaware 001-36571 20-4827488 101 Hartwell Avenue, Lexington, Massachusetts 02421 761-4646 N/A Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencement communications pursuant to Rule 13e-4 under the Exc...",
"T2 Biosystems Reports Fourth Quarter and Full-Year 2017 Financial Results and Business Update Quarterly Product Revenue Up 125% Year-Over-Year and 76% Over the Prior Quarter LEXINGTON, Mass., March 6, 2018 — T2 Biosystems, Inc. an emerging leader in the development and commercialization of innovative medical diagnostic products for critical unmet needs in healthcare, announced today operating highlights and financial results for the fourth quarter and year ended December 31, 2017. Fourth Quarter Business and Financial Performance Highlights:",
"Transcript of conference call held by T2 Biosystems, Inc. on March 6, 2018"
11/07/2017 8-K Quarterly results
Docs: "T2 Biosystems Reports Third Quarter 2017 Financial Results and Provides Company Update",
"Transcript of conference call held by T2 Biosystems, Inc. on November 2, 2017"
08/08/2017 8-K Quarterly results
Docs: "T2 BIOSYSTEMS REPORTS SECOND QUARTER 2017 FINANCIAL RESULTS; PROVIDES COMPANY UPDATE Sequential Quarterly Product Revenue Growth of 16.5%",
"Transcript of conference call held by T2 Biosystems, Inc. on August 3, 2017"
05/05/2017 8-K Form 8-K - Current report
02/16/2017 8-K Form 8-K - Current report
11/04/2016 8-K Form 8-K - Current report
08/03/2016 8-K Form 8-K - Current report
05/04/2016 8-K Quarterly results
Docs: "T2 Biosystems Reports 2016 First Quarter Results",
"Transcript of conference call held by T2 Biosystems, Inc. on May 2, 2016"
02/18/2016 8-K Form 8-K - Current report
11/06/2015 8-K Quarterly results
Docs: "T2 BIOSYSTEMS REPORTS 2015 THIRD QUARTER RESULTS Nine New Hospitals Signed Contracts in Q3; Six Hospitals Began Actively Testing",
"Transcript of conference call held by T2 Biosystems, Inc. on November 2, 2015"
08/07/2015 8-K Quarterly results
Docs: "T2 Biosystems Reports 2015 Second Quarter Results",
"Transcript of conference call held by T2 Biosystems, Inc. on August 4, 2015"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy